老年心肌梗死患者的侵入性治疗策略
本研究为前瞻性、多中心、随机试验,纳入英国48个中心≥75岁NSTEMI患者1518例,1:1随机分为侵入性策略组(冠脉造影+血运重建+最佳药物治疗)和保守策略组(仅最佳药物治疗)。中位随访4.1年,主要复合终点(心血管死亡或非致死性心肌梗死)发生率侵入性组25.6% vs 保守组26.3%(HR 0.94,95%CI 0.77–1.14,P=0.53),无显著差异。心血管死亡侵入性组15.8% vs 保守组14.2%(HR 1.11,95%CI 0.86–1.44);非致死性心肌梗死侵入性组11.7% vs 保守组15.0%(HR 0.75,95%CI 0.57–0.99)。操作并发症发生率低于1%。
要点
- ≥75岁NSTEMI患者中,侵入性策略未显著降低主要复合终点(心血管死亡或非致死性心梗)风险(HR 0.94,95%CI 0.77–1.14,P=0.53)。
- 非致死性心肌梗死发生率侵入性组11.7% vs 保守组15.0%(HR 0.75,95%CI 0.57–0.99)。
- 心血管死亡发生率侵入性组15.8% vs 保守组14.2%(HR 1.11,95%CI 0.86–1.44)。
- 操作并发症发生率低于1%。
- 研究纳入体弱或合并症负担高的患者,平均年龄82岁,32%体弱。
适用人群与场景
- 英国48个中心、年龄≥75岁的非ST段抬高型心肌梗死(NSTEMI)患者;体弱或合并症负担高的患者也符合纳入标准。
处置流程与药物剂量
- 侵入性策略组:接受冠状动脉造影和血运重建,并联合最佳可用药物治疗。
- 保守策略组:仅接受最佳可用药物治疗。
研究设计与关键结果
- 研究类型:前瞻性、多中心、随机试验,共纳入1518例患者,侵入性策略组753例,保守策略组765例。
- 人群特征:平均年龄82岁,女性占45%,体弱占32%。
- 主要终点(心血管死亡或非致死性心肌梗死复合终点)发生率:侵入性策略组25.6%(193例) vs 保守策略组26.3%(201例),HR 0.94(95%CI 0.77–1.14),P=0.53,中位随访4.1年。
- 心血管死亡发生率:侵入性策略组15.8% vs 保守策略组14.2%,HR 1.11(95%CI 0.86–1.44)。
- 非致死性心肌梗死发生率:侵入性策略组11.7% vs 保守策略组15.0%,HR 0.75(95%CI 0.57–0.99)。
- 操作并发症发生率低于1%。
证据类型、等级与局限
- 证据类型:前瞻性、多中心、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在≥75岁NSTEMI患者(包括体弱或合并症负担高者)中,侵入性策略未显著降低心血管死亡或非致死性心肌梗死复合终点风险;非致死性心肌梗死发生率在侵入性组较低,但心血管死亡发生率两组无显著差异。
- 操作并发症发生率低于1%。
指南或共识出处
- BHF SENIOR-RITA试验,ISRCTN注册号ISRCTN11343602,由英国心脏基金会资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether a conservative strategy of medical therapy alone or a strategy of medical therapy plus invasive treatment is more beneficial in older adults with non-ST-segment elevation myocardial infarction (NSTEMI) remains unclear.
METHODS: We conducted a prospective, multicenter, randomized trial involving patients 75 years of age or older with NSTEMI at 48 sites in the United Kingdom. The patients were assigned in a 1:1 ratio to a conservative strategy of the best available medical therapy or an invasive strategy of coronary angiography and revascularization plus the best available medical therapy. Patients who were frail or had a high burden of coexisting conditions were eligible. The primary outcome was a composite of death from cardiovascular causes (cardiovascular death) or nonfatal myocardial infarction assessed in a time-to-event analysis.
RESULTS: A total of 1518 patients underwent randomization; 753 patients were assigned to the invasive-strategy group and 765 to the conservative-strategy group. The mean age of the patients was 82 years, 45% were women, and 32% were frail. A primary-outcome event occurred in 193 patients (25.6%) in the invasive-strategy group and 201 patients (26.3%) in the conservative-strategy group (hazard ratio, 0.94; 95% confidence interval [CI], 0.77 to 1.14; P = 0.53) over a median follow-up of 4.1 years. Cardiovascular death occurred in 15.8% of the patients in the invasive-strategy group and 14.2% of the patients in the conservative-strategy group (hazard ratio, 1.11; 95% CI, 0.86 to 1.44). Nonfatal myocardial infarction occurred in 11.7% in the invasive-strategy group and 15.0% in the conservative-strategy group (hazard ratio, 0.75; 95% CI, 0.57 to 0.99). Procedural complications occurred in less than 1% of the patients.
CONCLUSIONS: In older adults with NSTEMI, an invasive strategy did not result in a significantly lower risk of cardiovascular death or nonfatal myocardial infarction (the composite primary outcome) than a conservative strategy over a median follow-up of 4.1 years. (Funded by the British Heart Foundation; BHF SENIOR-RITA ISRCTN Registry number, ISRCTN11343602.).
参考来源
- Kunadian V, Mossop H, Shields C, et al. Invasive Treatment Strategy for Older Patients with Myocardial Infarction. N Engl J Med. 2024. PMID: 39225274. doi:10.1056/NEJMoa2407791
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。